GSK H1 FY26 profit attributable to shareholders rises to $2.91 billion; turnover increases to $21.49 billion

• GSK posted H1 2026 profit after taxation of $3.21 billion, with earnings per share of 72.4c.
• Turnover totaled $21.49 billion, while operating profit came in at $3.72 billion.
• Vaccines turnover reached $5.94 billion, led by Shingrix at $2.57 billion.
• Specialty Medicines turnover was $9.39 billion, with HIV contributing $5.23 billion.
• General Medicines turnover totaled $6.16 billion, including Respiratory at $4.39 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.